| Aducanumab |
0 |
1 |
| Alzheimer Disease |
0 |
0.85 |
| Revenue and Practice Management |
0 |
0.6 |
| Medicare |
0 |
0.56 |
| Biologic Therapy |
0 |
0.49 |
| Social Determinants of Health |
0 |
0.37 |
| Clinical Research |
0 |
0.22 |
| Food and Drug Administration (FDA) |
0 |
0.22 |
| Brain |
0 |
0.17 |
| Monoclonal Antibody |
0 |
0.17 |
| Down Syndrome |
0 |
0.13 |
| Cardiovascular Imaging |
0 |
0.12 |
| Hospital |
0 |
0.09 |
| Health Insurance |
0 |
0.06 |
| Amyloid Plaque |
0 |
0.04 |
| Cognition |
0 |
0.04 |
| Dementia |
0 |
0.04 |
| Diversity |
0 |
0.04 |
| Echocardiography |
0 |
0.04 |
| Financial Reimbursement |
0 |
0.04 |
| Geriatrics |
0 |
0.04 |
| Grant |
0 |
0.04 |
| Hand |
0 |
0.04 |
| Health Care Inequities |
0 |
0.04 |
| Health Equity |
0 |
0.04 |
| Insurance |
0 |
0.04 |
| Medicaid |
0 |
0.04 |
| Private Practice |
0 |
0.04 |
| Washington |
0 |
0.04 |